Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
contact us
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Have a Project in Mind? Say Hi!
+1 800 123 456 789
+1 800 123 654 987
Mon - Sun: 10am - 10pm
27 Division St, New York,
NY 10002, USA
grido@mail.com
Newsroom
Press Releases
October 1, 2024
PR Neweswire
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Business Wire
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
November 30, 2023
Business Wire
Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy
October 19, 2023
Business Wire
Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases
April 4, 2023
Business Wire
Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor
November 8, 2022
Business Wire
Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy
1
2
Media
October 2, 2024
Drug Delivery Business
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
December 4, 2023
Medical Device Network
Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
April 4, 2023
Politico
Former FDA tobacco head: Smokers need a new tool to quit
March 31, 2023
Bloomberg
Ex-FDA Tobacco Head Advising Company on Smoker Cessation
February 24, 2023
Tobacco Reporter
Qnovia Raises $17 million for Nebulizer
January 8, 2023
Barron's
It’s Pharma Time: Why Merck and Lilly Are Buys, but Not Pfizer.
December 27, 2022
PharmaShots
Brian Quigley, CEO at Qnovia Shares his Views on Raising Series A Funding
December 19, 2022
Fierce Pharma
2023 forecast: The biopharma name changing craze and the shifting sands of corporate branding
December 16, 2022
Richmond Biz Journals
Qnovia aims to bring smoking cessation medical device to market in 2025
1
2
3
4
October 2, 2024
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
October 1, 2024
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
December 4, 2023
Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study
November 30, 2023
Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy
October 19, 2023
Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases
April 4, 2023
Former FDA tobacco head: Smokers need a new tool to quit
April 4, 2023
Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor
March 31, 2023
Ex-FDA Tobacco Head Advising Company on Smoker Cessation
1
2
3
…
5
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;}
Qnovia
